OAM
VRCA icon

Oxford Asset Management’s Verrica Pharmaceuticals VRCA Stock Holding History

Oxford Asset Management’s Portfolio VRCA Stock Details VRCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-3,929
Closed -$772K – 1943
2018
Q2 		$772K Buy
+3,929
New +$770K 0.01% 1155

Other funds holding VRCA

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kornitzer Capital Management Shawnee Mission, Kansas $4.79B AUM 30.56% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
CI
Conning Inc Hartford, Connecticut $3.34B AUM 25.19% 1-Year Est. Return

Oxford Asset Management's VRCA Position: Q3 2018 in Review

Oxford Asset Management sold out of Verrica Pharmaceuticals (VRCA) in Q3 2018, closing a stake of 3,929 shares — an estimated $772K sold.

Oxford Asset Management first reported a position in VRCA in Q2 2018 and held it in 1 quarter. The position peaked at $772K in Q2 2018. 45 funds tracked by Wall St. Rank hold VRCA as of Q3 2018.

  • Oxford Asset Management reported no remaining Verrica Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Oxford Asset Management sold 3,929 Verrica Pharmaceuticals shares in Q3 2018, an estimated $772K.
  • Oxford Asset Management first reported a position in Verrica Pharmaceuticals in Q2 2018 and held it in 1 quarter.
  • Oxford Asset Management's Verrica Pharmaceuticals position peaked at $772K in Q2 2018.
  • 45 funds tracked by Wall St. Rank held Verrica Pharmaceuticals as of Q3 2018.

Based on Oxford Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.